Avatrombopag tablets medical insurance price

Avatrombopag was approved by the FDA in 2018 for the treatment of thrombocytopenia in adults with chronic liver disease (CLD) who are planning to undergo medical or dental surgery. It is the first drug approved by the FDA for this indication. In two phase 3 randomized trials, avatropopag was superior to placebo in reducing the need for platelet transfusions or bleeding rescue procedures in patients with thrombocytopenia and CLD undergoing planned surgery.

Additionally, once-daily oral administration of avatrombopag increased platelet counts above baseline in patients with chronic ITP in a 28-day Phase 2 study. These effects were also reflected in a randomized phase 3 study in which avatropopag was superior to placebo in increasing platelet responses and cumulative weeks of durable platelet responses in patients with chronic immune thrombocytopenia ITP. In all of these clinical studies, avatropopag was generally well tolerated. In these studies, there was no evidence of increased thromboembolic events, hepatotoxicity, or significant food interactions with avatrombopag.

The original drug of avatrombopag has been launched in China and has entered the scope of Class B medical insurance, but it can only be reimbursed for eligible patients. The price of a common 20mg*15 tablets may be more than 7,000 yuan per box. The reimbursement ratio is different in different regions, and the price after reimbursement may be different. The original drug of avatrombopag marketed overseas is more expensive. It is understood that there are generic drugs of avatrombopag available overseas, and their pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of a box of 20mg*30 tablets in Laos pharmaceutical production specifications may be around RMB 1,000 (the price may fluctuate due to exchange rates).